M. Monier‐Faugere

发表

Early chronic kidney disease-mineral bone disorder stimulates vascular calcification

K. Hruska, H. Malluche, Yifu Fang, 2013, Kidney international.

Moderately high consumption of ethanol suppresses bone resorption in ovariectomized but not in sexually intact adult female rats.

H. Malluche, P. Fanti, M. Monier‐Faugere, 1997, Alcoholism, clinical and experimental research.

Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease.

H. Malluche, P. Fanti, M. Monier‐Faugere, 2003, Kidney international.

Parathyroid hormone assays--evolution and revolutions in the care of dialysis patients.

M. Monier‐Faugere, H. Mawad, H. Malluche, 2003, Clinical nephrology.

Influence of the parathyroid glands on bone metabolism

N. Koszewski, H. Malluche, J. Williams, 2006, European journal of clinical investigation.

Femoral bone mineral density reflects histologically determined cortical bone volume in hemodialysis patients

A. Branscum, H. Malluche, M. Monier‐Faugere, 2010, Osteoporosis International.

Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients.

Aníbal Ferreira, H. Malluche, C. Gil, 2008, Journal of the American Society of Nephrology : JASN.

Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients

H. Malluche, M. Monier‐Faugere, H. Mawad, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Chapter 8 – Bone Biopsies: A Modern Approach

H. Malluche, M. Monier‐Faugere, M. C. Langub, 1998 .

High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis.

H. Malluche, D. Davenport, M. Monier‐Faugere, 2015, Journal of the American Society of Nephrology : JASN.

The link between bone and coronary calcifications in CKD-5 patients on haemodialysis.

A. Branscum, H. Malluche, E. Ok, 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Low bone volume--a risk factor for coronary calcifications in hemodialysis patients.

A. Branscum, Aníbal Ferreira, H. Malluche, 2009, Clinical journal of the American Society of Nephrology : CJASN.

Coronary artery calcification in CKD-5D patients is tied to adverse cardiac function and increased mortality

V. Sorrell, H. Malluche, D. Davenport, 2016, Clinical nephrology.

Bone disease after renal transplantation

H. Malluche, M. Monier‐Faugere, J. Herberth, 2010, Nature Reviews Nephrology.

Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis.

H. Malluche, M. Monier‐Faugere, Z. Geng, 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis.

H. Malluche, F. Kirçelli, E. Ok, 2016, Journal of the American Society of Nephrology : JASN.

Bone biopsy in patients with osteoporosis

H. Malluche, M. Monier‐Faugere, H. Mawad, 2007, Current osteoporosis reports.

Bone Quality in Chronic Kidney Disease Patients: Current Concepts and Future Directions − Part II

M. Monier‐Faugere, A. El-Husseini, K. Asadipooya, 2021, Kidney Diseases.

Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis.

H. Malluche, D. Davenport, M. Monier‐Faugere, 2014, Clinical journal of the American Society of Nephrology : CJASN.

Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study.

H. Malluche, M. Monier‐Faugere, P. Magnusson, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis

H. Malluche, M. Monier‐Faugere, V. David, 2014, Clinical nephrology.

Low-energy fractures without low T-scores characteristic of osteoporosis: a possible bone matrix disorder.

H. Malluche, D. Pienkowski, M. Monier‐Faugere, 2013, The Journal of bone and joint surgery. American volume.

Parathyroid Hormone/Parathyroid Hormone‐Related Peptide Type 1 Receptor in Human Bone

N. Koszewski, H. Malluche, M. Monier‐Faugere, 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.

H. Malluche, E. Slatopolsky, M. Monier‐Faugere, 1999, Kidney international.

The Phytoestrogen Genistein Reduces Bone Loss in Short-Term Ovariectomized Rats

P. Morris, H. Malluche, P. Fanti, 1998, Osteoporosis International.

Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy.

N. Koszewski, H. Malluche, M. Monier‐Faugere, 1996, Kidney international.

Quality assurance-quality control in bone histopathology and bone histomorphometry.

M. Monier‐Faugere, 1993, Bone.

Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.

D. Pahr, H. Malluche, R. Marculescu, 2016, Kidney international.

Diagnosis of low bone mass in CKD-5D patients

H. Malluche, D. Davenport, M. Monier‐Faugere, 2015, Clinical nephrology.

Histologic Abnormalities of Bone before and after Kidney Transplantation

H. Malluche, M. Monier‐Faugere, 2005 .

Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients.

D. Rao, J. Yee, H. Malluche, 2009, Clinical journal of the American Society of Nephrology : CJASN.

The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients.

A. Branscum, H. Malluche, M. Monier‐Faugere, 2009, Clinical nephrology.

Effects of treatment of renal osteodystrophy on bone histology.

H. Malluche, M. Monier‐Faugere, H. Mawad, 2008, Clinical journal of the American Society of Nephrology : CJASN.

High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation.

H. Malluche, M. Monier‐Faugere, H. Mawad, 2000, Journal of the American Society of Nephrology : JASN.

Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism.

P. Fanti, M. Monier‐Faugere, B. Sawaya, 2002, Clinical nephrology.

Prevalence of low bone formation in untreated patients with osteoporosis

H. Malluche, M. Monier‐Faugere, Florence Lima, 2022, PloS one.

An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.

H. Malluche, W. Goodman, J. Coburn, 2008, Clinical nephrology.

Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years.

H. Malluche, C. Swanepoel, M. Monier‐Faugere, 2008, Clinical nephrology.

Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure.

W. C. O'Neill, Xiaonan H. Wang, H. Malluche, 2009, Kidney international.

Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors

D. Davenport, M. Monier‐Faugere, H. Malluche, 2017, Osteoporosis International.

Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure.

N. Koszewski, H. Malluche, M. Monier‐Faugere, 2003, Endocrinology.

Hyperphosphatemia: pharmacologic intervention yesterday, today and tomorrow.

M. Monier‐Faugere, H. Malluche, 2000, Clinical nephrology.

Calcitonin, somatostatin and ACTH immunoreactive cells in a case of familial bilateral thyroid medullary carcinoma

J. Hassoun, M. Monier‐Faugere, L. Andrac, 1982, Cancer.

Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease.

H. Malluche, M. Monier‐Faugere, H. Mawad, 2007, Clinical journal of the American Society of Nephrology : CJASN.

Risk of adynamic bone disease in dialyzed patients.

M. Monier‐Faugere, H. Malluche, 1992, Kidney international. Supplement.

The role of bone biopsy in the management of patients with renal osteodystrophy.

M. Monier‐Faugere, H. Malluche, 1994, Journal of the American Society of Nephrology : JASN.

Pth 1-84, Pth fragments and bone turnover.

H. Malluche, M. Monier‐Faugere, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Renal osteodystrophy: what's in a name? Presentation of a clinically useful new model to interpret bone histologic findings.

H. Malluche, M. Monier‐Faugere, Monier-Faugere Mc, 2006, Clinical nephrology.

Animal models for the study of bone loss after cessation of ovarian function.

H. Malluche, M. Monier‐Faugere, J. B. Rodgers, 1993, Bone.

Evidence for abnormal calcium homeostasis in patients with adynamic bone disease.

H. Malluche, M. Monier‐Faugere, P. Roth, 1994, Kidney international.

Calcitriol pulse therapy in patients with end-stage renal failure.

M. Monier‐Faugere, H. Malluche, 1994, Current opinion in nephrology and hypertension.

Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients.

H. Malluche, M. Monier‐Faugere, Z. Geng, 2001, Kidney international.

Calcitonin Alters Bone Quality in Beagle Dogs

A. Boskey, N. Camacho, H. Malluche, 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.

B. Freedman, K. Hruska, H. Malluche, 2014, Journal of the American Society of Nephrology : JASN.

Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation.

L. Donahue, T. Clemens, J. Fagin, 2000, Endocrinology.

Morphological and biochemical changes in muscle and peripheral nerve in Fabry's disease

M. Monier‐Faugere, F. Van hoof, J. Pellissier, 1981, Muscle & nerve.

Sclerostin and Dickkopf-1 in renal osteodystrophy.

A. Branscum, D. Fardo, H. Malluche, 2011, Clinical journal of the American Society of Nephrology : CJASN.

Systemic osteopenia and mineralization defect in patients with ankylosing spondylitis.

V. Szejnfeld, M. Monier‐Faugere, H. Malluche, 1997, The Journal of rheumatology.

Bone Quality in CKD Patients: Current Concepts and Future Directions – Part I

M. Monier‐Faugere, A. El-Husseini, K. Asadipooya, 2021, Kidney Diseases.

The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?

H. Malluche, M. Monier‐Faugere, H. Mawad, 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Differences in bone quality in low- and high-turnover renal osteodystrophy.

H. Malluche, D. Pienkowski, M. Monier‐Faugere, 2012, Journal of the American Society of Nephrology : JASN.

Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients.

M. Monier‐Faugere, H. Malluche, 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Uremic bone disease: current knowledge, controversial issues, and new horizons.

H. Malluche, M. Monier‐Faugere, 1991, Mineral and Electrolyte Metabolism.

The role of bone biopsy in clinical practice and research.

M. Monier‐Faugere, M. C. Langub, H. Malluche, 1999, Kidney international. Supplement.

Role of cytokines in renal osteodystrophy

M. Monier‐Faugere, H. Malluche, 1997, Current opinion in nephrology and hypertension.

Pathogenesis and histology of renal osteodystrophy

M. Monier‐Faugere, M. C. Langub, H. Malluche, 2010, Osteoporosis International.

A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs

F. Bauss, H. Malluche, M. Monier‐Faugere, 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bone — Normal Structure and Physiology

H. Malluche, M. Monier‐Faugere, M. C. Langub, 2002 .

Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties

A. Boskey, F. Bauss, H. Malluche, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study.

A. Branscum, H. Malluche, M. Monier‐Faugere, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Calcitonin prevents bone loss but decreases osteoblastic activity in ovariohysterectomized beagle dogs

H. Malluche, M. Monier‐Faugere, Z. Geng, 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure.

N. Koszewski, H. Malluche, M. Monier‐Faugere, 1997, Journal of the American Society of Nephrology : JASN.

Bone Quality and Fractures in Women With Osteoporosis Treated With Bisphosphonates for 1 to 14 Years

H. Malluche, D. Pienkowski, M. Monier‐Faugere, 2021, JBMR plus.

Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation.

V. Briner, M. Monier‐Faugere, G. Thiel, 1995, Transplantation.

Higher mineralized bone volume is associated with a lower plain X-Ray vascular calcification score in hemodialysis patients

Aníbal Ferreira, H. Malluche, A. Papoila, 2017, PloS one.

Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure.

F. Bauss, H. Malluche, M. Monier‐Faugere, 2000, Clinical nephrology.

FGF-23 and sclerostin in serum and bone of CKD patients

H. Malluche, M. Monier‐Faugere, V. David, 2023, Clinical nephrology.

Absence of adynamic bone disease in African-Americans with CKD stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio.

J. Yee, H. Malluche, Y. Osman, 2009, Clinical nephrology.